UBS cuts BBVA to “neutral” on fading EPS upside, Turkey risks

UBS downgraded BBVA to neutral from buy and cut its 12-month price target to €20.5 from €22.3, implying only about 5% upside from the current €19.57 share price. The broker reduced 2026-2028 EPS by 1-2% and flagged Turkey as the main risk, citing a roughly 50% rise in oil prices, higher loan-loss provisions, and slower disinflation. UBS expects BBVA’s ROTE at 19.4% in 2026 and 20.5% in 2027, while CET1 is seen slipping from 12.7% to 12.2% by end-2028 as capital is returned to shareholders.

Analysis

The key change here is not the modest EPS cut; it is the collapse in the rerating setup. BBVA has already re-rated to sector parity, so the marginal buyer now needs either faster earnings upgrades or a cleaner capital-return story to pay up again. UBS is effectively saying the stock has moved from a “multiple expansion” trade to a “show-me” trade, which usually compresses upside and makes any disappointment in Mexico or Turkey disproportionately painful.

Turkey is the hidden convexity. When a large emerging-market earnings engine is tied to an inflation/currency regime that can be hit by oil, the market stops valuing the franchise on normalized earnings and starts discounting policy error risk. That creates second-order pressure on BBVA’s perceived capital flexibility: if Garanti becomes less dependable, the market will question how sustainable the payout cadence is even if CET1 still trends within management’s guardrails.

The contrarian angle is that consensus may be over-indexing on the near-term rate path and underestimating how much of BBVA’s premium European profitability is already structurally earned. If Mexico remains resilient and Turkey merely muddles through rather than deteriorates, the downside from here is likely more about time decay than a sharp de-rating. In other words, the stock is less a broken story than an expensive one, and expensive banks can grind lower for months before fundamentals fully catch down.

For UBS specifically, the preference shift is a mild relative-value negative for BBVA and a subtle support for Santander in Spain, but the cleaner expression is to fade BBVA versus the broader European bank basket rather than trying to time outright beta. The high payout profile limits absolute downside, yet that same feature caps the scope for multiple re-expansion unless earnings momentum re-accelerates. Near term, any oil spike or Turkey inflation surprise would likely hit BBVA first, with the market pricing in a bigger discount to emerging-market earnings quality within days rather than quarters.

Key Decisions for Investors

• Short BBVA vs. long SX7E/SXXP banks basket over 1-3 months; thesis is BBVA has already closed its historic discount and now has less rerating optionality than peers.
• For existing BBVA holders, sell covered calls 5-8% above spot with 2-4 month tenor; harvest yield while capping upside in a low-catalyst setup.
• Buy Santander vs. short BBVA as a Spain-relative pair over the next quarter; UBS’s preference shift improves the risk/reward of switching exposure rather than adding net sector risk.
• If crude oil extends higher for 4-6 weeks, add BBVA downside via puts or put spreads targeting the next earnings window; Turkey is the most underappreciated transmission channel.
• Avoid chasing BBVA on dips unless consensus EPS revisions turn positive again; without that, the stock is likely to trade as a high-yield value trap rather than a growth compounder.